Both are sold for gut inflammation, and KPV is the more interesting of the two on route: it is taken up by intestinal epithelium through the PepT1 transporter, which makes oral dosing mechanistically plausible in a way it is not for most peptides.
Side by side
| KPV | BPC-157 | |
|---|---|---|
| Class | Anti-inflammatory tripeptide | Body-protection pentadecapeptide |
| Status | Research compound | Research compound |
| Route | Subcutaneous injection | Subcutaneous injection |
| Typical vials | 5 mg, 10 mg | 2 mg, 5 mg, 10 mg |
| Dose range | 200 mcg to 500 mcg | 250 mcg to 500 mcg |
| Frequency | Once daily | 1 to 2 times daily |
| Half-life | No human data | No human data |
| Dosing unit | micrograms | micrograms |
Pharmacokinetics
No curves are shown, on purpose.
No published human pharmacokinetics for KPV or BPC-157. Drawing one curve against an absent one would imply a comparison that cannot be made.
What the evidence supports
These grade how well each outcome has been studied in humans, never how well either compound works. A strong grade can sit on a negative result.
Both top out at the same tier of evidence: Animal only. Where they differ is in which outcomes have been asked about, not in how well either has been studied overall.
KPV
| Outcome | Evidence |
|---|---|
| Intestinal inflammation | Animal only |
| Skin inflammation | Animal only |
| PepT1-mediated epithelial uptake | Mechanistic only |
| Any outcome in humans | No data |
BPC-157
| Outcome | Evidence |
|---|---|
| Gastrointestinal protection | Animal only |
| Tendon and ligament healing | Animal only |
| Any outcome in humans | No data |
How to choose
KPV has a real reason to work orally
PepT1 uptake is a specific, documented transport route. Most oral peptide claims have nothing like this behind them.
Neither has a published human trial
KPV's evidence is cell and animal work on inflammation. BPC-157's is rodent.
KPV is a fragment of alpha-MSH
It carries the anti-inflammatory activity without the pigmentation effects of the parent hormone, which is the appeal.
At the syringe
At the default setup on each compound's own page, a 5 mg vial in 2 mL puts 25 mcg on every insulin unit, while a 5 mg vial in 2 mL puts 25 mcg on every unit. That is the number that decides whether a dose lands on a readable mark, and it is set by how much water goes in, not by the compound.